Regenerative Medical Technology (RMTG) Cost of Revenue (2018 - 2026)

Regenerative Medical Technology's Cost of Revenue history runs 9 years deep, the most recent figure standing at $872862.0 for Q1 2026.

• In Q1 2026, Cost of Revenue rose 107.6% year-over-year to $872862.0; the TTM figure through Mar 2026 stood at $2.7 million (up 88.22% YoY), while the FY2025 annual figure was $2.3 million, up 78.26% from the prior year.
• Cost of Revenue for Q1 2026 stood at $872862.0, up from $792427.0 in the prior quarter.
• The five-year high for Cost of Revenue was $872862.0 in Q1 2026, with the low at $102779.0 in Q3 2022.
• The 5-year median for Cost of Revenue is $248043.0 (2024), against an average of $343195.1.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 1201.45% in 2022, then decreased 28.57% in 2023.
• Regenerative Medical Technology's Cost of Revenue stood at $207442.0 in 2022, then decreased by 12.83% to $180818.0 in 2023, then surged by 193.47% to $530640.0 in 2024, then surged by 49.33% to $792427.0 in 2025, then increased by 10.15% to $872862.0 in 2026.
• Business Quant data shows RMTG's Cost of Revenue at $872862.0 in Q1 2026, $792427.0 in Q4 2025, and $678977.0 in Q3 2025.